RE:RE:Now that we’re all AEZS shareholdersscarface9 wrote: Will there be a restructuring and lay offs at head office. Only one CEO, CFO needed now, so somebody has to go. Plus a lot of other positions will now be redundant and can be consolidated.
With the completion of AEZS's diagnostic clinical trial the costs for the clinical trial for the test falls off. They can streamline human infrastructure as only one CEO, CFO, VP Business Development, etc., and IR function is needed. The collective number of individuals on the Board of Directors shrinks saving money. The two companies can also share human infrastrucutre as human trials advance. The TSX-V listing and associated costs will also be eliminated saving money. AEZS is already incurring costs for the TSX and NASDAQ.
The combined company will have more news flow and greater critical mass to attract investors. AEZS already has already had one analyst(H.C. Wainwright) with a US$15 target. The combined company is well positioned to tell its story as key milestones are reached and the daisy chain of events unfolds.